Loading…
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $39M | $14M | $11M | $14M | 9.5% | -5.8% | -18.7% |
| 2024 | $41M | $16M | $14M | $15M | 11.8% | -18.6% | -16.6% |
| 2023 | $50M | $23M | $17M | $22M | 13.0% | -3.9% | 1.0% |
| 2022 | $52M | $27M | $16M | $20M | 14.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 52.28 | 50.22 | 40.90 | 38.52 |
| Cost Of Revenue | 20.09 | 20.19 | 16.76 | 16.52 |
| Gross Profit | 32.20 | 30.04 | 24.14 | 22 |
| Operating Expense | 12.41 | 13.26 | 10.55 | 10.60 |
| Operating Income | 19.79 | 16.78 | 13.59 | 11.40 |
| EBITDA | 26.87 | 23.14 | 16.44 | 14.41 |
| EBIT | 19.79 | 16.78 | 13.59 | 11.40 |
| Pretax Income | 20.66 | 20.09 | 16.80 | 14.11 |
| Tax Provision | 4.19 | 3.45 | 2.93 | 2.82 |
| Net Income | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Common Stockholders | 16.47 | 16.64 | 13.87 | 11.29 |
| Total Expenses | 32.49 | 33.45 | 27.31 | 27.12 |
| Research And Development | 0.49 | 0.56 | 0.81 | 0.67 |
| Selling General And Administration | 11.91 | 12.70 | 9.74 | 9.93 |
| Normalized EBITDA | 26.21 | 20.11 | 13.07 | 11.60 |
| Normalized Income | 15.95 | 14.12 | 11.09 | 9.04 |
| Basic EPS | 5.69 | 4.58 | 4.16 | 0 |
| Diluted EPS | 4.52 | 4.57 | 3.96 | 0 |
| Tax Effect Of Unusual Items | 0.13 | 0.52 | 0.59 | 0.56 |
| Tax Rate For Calcs | 0.20 | 0.17 | 0.17 | 0.20 |
| Total Unusual Items | 0.66 | 3.04 | 3.37 | 2.81 |
| Total Unusual Items Excluding Goodwill | 0.66 | 3.04 | 3.37 | 2.81 |
| Net Income From Continuing Operation Net Minority Interest | 16.47 | 16.64 | 13.87 | 11.29 |
| Reconciled Depreciation | 7.08 | 6.37 | 2.85 | 3.01 |
| Reconciled Cost Of Revenue | 20.09 | 20.19 | 16.76 | 16.52 |
| Net Income From Continuing And Discontinued Operation | 16.47 | 16.64 | 13.87 | 11.29 |
| Total Operating Income As Reported | 19.79 | 16.78 | 13.59 | 11.40 |
| Diluted Average Shares | 3.64 | 3.64 | 3.50 | 0 |
| Basic Average Shares | 3.63 | 3.63 | 3.34 | 0 |
| Diluted NI Availto Com Stockholders | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Including Noncontrolling Interests | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Continuous Operations | 16.47 | 16.64 | 13.87 | 11.29 |
| Other Income Expense | 0.87 | 3.31 | 3.21 | 2.71 |
| Other Non Operating Income Expenses | 0.21 | 0.28 | -0.16 | -0.10 |
| Gain On Sale Of Security | 0.66 | 3.04 | 3.37 | 2.81 |
| Selling And Marketing Expense | 1.51 | 1.69 | 1.90 | 2.05 |
| General And Administrative Expense | 10.41 | 11.02 | 7.83 | 7.88 |
| Other Gand A | 10.41 | 11.02 | 7.83 | 7.88 |
| Operating Revenue | 52.28 | 50.22 | 40.90 | 38.52 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Utah Medical Products, Inc.this co. | UTMD | $207M | 19.24↑ premium | 1.74 | 9.5% | 7.91 |
| Keros Therapeutics, Inc. | KROS | $220M | 4.83 | 0.72 | 28.7% | -0.72 |
| Sight Sciences, Inc. | SGHT | $216M | - | 3.32 | -60.1% | -4.83 |
| LifeMD, Inc. | LFMD | $210M | - | 8.93 | 62.0% | -27.13 |
| Electromed, Inc. | ELMD | $208M |
| 24.37 |
| 4.57 |
| 17.4% |
| 15.06 |
| OraSure Technologies, Inc. | OSUR | $205M | - | 0.61 | -20.2% | -0.32 |
| Atrium Therapeutics, Inc. | RNA | $202M | - | -3.21 | -37.0% | - |
| OmniAb, Inc. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| Replimune Group, Inc. | REPL | $197M | - | 0.90 | -59.5% | -0.01 |
| Peer Median | - | 14.60 | 0.82 | -22.2% | -0.72 | |